BL 1826

Drug Profile

BL 1826

Alternative Names: Nicotine sublingual aerosol spray

Latest Information Update: 03 Dec 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioglan Pharma [CEASED]
  • Class Nicotine replacement therapy
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Smoking withdrawal

Most Recent Events

  • 03 Dec 2002 Discontinued - Phase-II for Smoking withdrawal in USA (Sublingual)
  • 21 Aug 2001 Phase-II clinical trials for Smoking withdrawal in USA (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top